Interactions

Displaying 401 - 600 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents	Info Source
6263	Rilpivirine Atorvastatin 648	Rilpivirine	150 mg daily	No significant change	Atorvastatin	40 mg daily	Atorvastatin Cmin decreased 15%; Cmax increased 35%		Green: Administer standard doses	Administer standard doses
6279	Rilpivirine RIF 664	Rilpivirine	150 mg daily	Rilpivirine AUC decreased 80%; Cmin decreased 89%; Cmax decreased 69%	Rifampin	600 mg daily	No significant change	Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Use alternative agents
6959	Rilpivirine Esomeprazole 123	Rilpivirine			Esomeprazole			Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Contraindicated. Use alternative agents.	H2-antagonists if administered at least 12 hours before rilpivirine or at least 4 hours after rilpivirine.	DHHS Adult ARV Guidelines
6264	Rilpivirine DTG 649	Rilpivirine	25 mg daily	Rilpivirine Cmin increased 21%	Dolutegravir	50 mg daily	Dolutegravir Cmin increased 22%		Green: Administer standard doses	Administer standard doses
6280	Rilpivirine RFB 665	Rilpivirine	150 mg daily	Rilpivirine AUC decreased 46%; Cmin decreased 49%; Cmax decreased 35%	Rifabutin	300 mg daily		Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Use alternative agents
6265	Rilpivirine Ethinyl estradiol / Norethindrone acetate 650	Rilpivirine	25 mg daily	No significant change	Ethinyl estradiol / Norethindrone acetate	0.035 mg daily ethinyl estradiol with 1 mg norethindrone daily	Ethinyl estradiol Cmax increased 17%; Norethindrone: no significant change		Green: Administer standard doses	Administer standard doses
6266	Rilpivirine Simeprevir 651	Rilpivirine	25 mg daily x 11 days	Rilpivirine Cmin increased 25%	Simeprevir	150 mg daily x 11 days	No significant change		Green: Administer standard doses	Administer standard doses
6267	Rilpivirine Sildenafil 652	Rilpivirine	75 mg daily	No significant change	Sildenafil	50 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6268	Rilpivirine Chlorzoxazone 653	Rilpivirine	150 mg daily	Rilpivirine AUC increased 25%; Cmin increased 18%; Cmax increased 17%	Chlorzoxazone	500 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6269	Rilpivirine SOF 654	Rilpivirine	25 mg daily		Sofosbuvir	400 mg x 1	Sofosbuvir Cmax increased 21%		Green: Administer standard doses	Administer standard doses
6270	Rilpivirine Famotidine 655	Rilpivirine	150 mg x 1	No significant change	Famotidine	40 mg x 1 taken 12 hours before rilpivirine			Green: Administer standard doses	Administer standard doses
6383	Atazanavir RFB 768	Atazanavir	400 mg daily on days 1-28	Atazanavir Cmax increased 34%	Rifabutin	150 mg daily on days 15-28	Not reported		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6399	Atazanavir Omeprazole 784	Atazanavir	400 mg daily x 12 d	Atazanavir AUC decreased 94%, Cmax decreased 96%, Cmin decreased 95%	Omeprazole	40 mg daily x 5 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6415	Atazanavir Lamotrigine 800	Atazanavir	Atazanavir 400mg daily or Atazanavir 300 mg with Ritonavir 100 mg daily	No significant change	Lamotrigine	100 mg daily	AUC decreased 32%	Atazanavir with ritonavir may decrease lamotrigine plasma concentrations, Atazanavir without ritonavir is most likely not clinically significant	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of lamotrigine	No dose adjustment necessary if administering lamotrigine and atazanavir alone. If administering lamotrigine and atazanavir plus ritonovir, lamotrigine maintenance dose may need to be increased.
6431	Atazanavir Acetaminophen 816	Atazanavir	300 mg atazanavir daily with 100 mg ritonavir daily on d 11-20	Atazanavir Cmin increased 26%	Acetaminophen	1 gram BID on days 1-20			Green: Administer standard doses	Administer standard doses
6447	Atazanavir St. John's Wort (Hypericum perforatum) 832	Atazanavir			St. John's Wort			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6463	Atazanavir Ticagrelor 848	Atazanavir			Ticagrelor			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6479	Atazanavir Rivaroxaban 864	Atazanavir			Rivaroxaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative agents	Dabigatran
6384	Atazanavir Rosuvastatin 769	Atazanavir	300 mg atazanavir daily with ritonavir 100 mg daily		Rosuvastatin	10 mg daily	Rosuvastatin AUC increased 213%, Cmax increased 600%	Potential for increased rosuvastatin adverse effects (e.g. myopathy)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily.	Pravastatin, atorvastatin
6400	Atazanavir Lansoprazole 785	Atazanavir	400 mg daily	Atazanavir AUC decreased 94%, Cmax decreased 91%, half-life: no significant change	Lansoprazole	60 mg daily x 2 doses		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6416	Atazanavir Methadone 801	Atazanavir	400 mg daily on d 2-15		Methadone	stable dose on d 1-15	Total methadone Cmax decresed 15%	Potential decreased methadone effects (withdrawl, inadequate pain control, cravings)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6432	Atazanavir Alfuzosin 817	Atazanavir			Alfuzosin				Red: Avoid combination	Do not coadminister: Increased levels of alfuzosin	Contraindicated. Use alternative agents.
6448	Atazanavir Phenobarbital 833	Atazanavir			Phenobarbital			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6464	Atazanavir Vorapaxar 849	Atazanavir			Vorapaxar			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6480	Atazanavir Apixaban 865	Atazanavir			Apixaban			Increased apixaban levels, Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefitsÊof using this combination	Consider using alternative agents	Dabigatran
6369	Atazanavir DRV 754	Atazanavir	300 mg daily	Atazanavir Cmin increased 52%	Darunavir	400 mg BID with ritonavir 100 mg BID	No significant change		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of antiretrovirals	If used in combination, atazanavir may be given in conjunction with darunavir / ritonavir at study doses (300mg daily plus 400 / 100 mg daily)
6385	Atazanavir Sildenafil 770	Atazanavir			Sildenafil			Potentially increased sildenafil effects (eg, hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	For erectile dysfunction, initiate sildenafil (Viagra) 25 mg every 48 hours and monitor for adverse effects. Do not coadminister if using sildenafil for pulmonary arterial hypertension.
6401	Atazanavir Pantoprazole 786	Atazanavir			Pantoprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6417	Atazanavir LDV/SOF 802	Atazanavir	Atazanavir / ritonavir 300 mg / 100mg daily given simultaenously for 10 days plus emtricitabine / tenofovir DF 200mg / 300mg daily	Atazanavir AUC(tau) increased 43%	Ledipasvir / Sofosbuvir	90 / 400 mg	Ledipasvir AUC(tau) increased 134%, Cmax increased 75%	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Green: Administer standard doses	Administer standard doses	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
6433	Atazanavir Irinotecan 818	Atazanavir			Irinotecan				Red: Avoid combination	Do not coadminister: Increased levels of irinotecan	Contraindicated. Use alternative agents.
6449	Atazanavir Phenytoin 834	Atazanavir			Phenytoin			Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6465	Atazanavir Telithromycin 850	Atazanavir			Telithromycin			Potential for increased telithromycin effects. (e.g. may cause QTc prolongation)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Avoid combination or use alternative agents
6370	Atazanavir RTV 755	Atazanavir	300 mg daily on days 1-20	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	Ritonavir	100 mg daily on days 11-20	Not studied	Increased atazanavir effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
6386	Atazanavir Tadalafil 771	Atazanavir			Tadalafil			Potentially increased tadalafill effects (eg, hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased tadalafil levels	For erectile dysfunction initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
6402	Atazanavir Rabeprazole 787	Atazanavir			Rabeprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6418	Atazanavir LDV/SOF 803	Atazanavir	Atazanavir / ritonavir 300 mg / 100mg daily given simultaenously for 10 days plus emtricitabine / tenofovir DF 200mg / 300mg daily	Atazanavir AUC increased 27%, Cmin increased 63%	Ledipasvir / Sofosbuvir	90 / 400 mg	Ledipasvir AUC(tau) increased 96%, Cmax increased 68%.	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Green: Administer standard doses	Administer standard doses	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
6434	Atazanavir SOF/VEL/VOX 819	Atazanavir			Sofosbuvir / Velpatasvir / Voxilaprevir				Red: Avoid combination	Do not coadminister: Increased levels of voxilaprevir	Contraindicated. Use alternative agents.
6450	Atazanavir CBZ 835	Atazanavir			Carbamazepine			Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Contraindicated. Use alternative agents.
6466	Atazanavir Atovaquone 851	Atazanavir	300 mg with 100 mg ritonavir daily	Not reported	Atovaquone	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 46%, Cmax decreased 49%	Potential compromised antimalarial activity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established. If coadministering monitor for anti-malarial efficacy.
6371	Atazanavir Clarithromycin 756	Atazanavir	400 mg daily on days 1-10	Atazanavir AUC increased 28%, Cmax no significant change, Cmin increased 91%	Clarithromycin	500 mg BID on days 7-11 and 18-21	Clarithromycin AUC increased 94%, Cmax increased 50%, Cmin decreased 62%, 14-hydroxyclarithromycin AUC decreased 70%, Cmax decreased 72%, Cmin increased 164%	Potential for increased clarithromycin effects. (e.g. may cause QTc prolongation).	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	Reduce clarithromycin dose by 50%	Azithromycin
6387	Atazanavir Aluminum and magnesium hydroxide antacid 772	Atazanavir			Aluminum and magnesium hydroxide antacid				Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Separate administration of atazanavir / cobicistat and antacids by a minimum of 2 hours.
6403	Atazanavir EFV 788	Atazanavir	400 mg daily on days 1-6 then 300 mg with ritonavir 100 mg daily on days 7-20	Atazanavir (all values compared to atazanavir 400 mg daily) AUC increased 39% , Cmax no significant change, Cmin increased 48%	Efavirenz	600 mg daily x days 7-20	Not reported	Potential for increased atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6419	Atazanavir Posaconazole 804	Atazanavir	300 mg daily with 100 mg ritonavir daily	Atazanavir AUC increased 146%, Cmax increased 53%	Posaconazole	400 mg BID		Potential for increased atazanavir adverse effects	Green: Administer standard doses	Administer standard doses	Monitor closely for atazanavir adverse effects during coadministration
6435	Atazanavir Triazolam 820	Atazanavir			Triazolam			Potential for increased triazolam adverse effects (eg, increased sedation, confusion, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Contraindicated. Use alternative agents.	Lorazepam, Oxazepam, Temazepam, Trazodone
6451	Atazanavir RIF 836	Atazanavir	300 mg with 200 mg ritonavir daily x 10 d	Atazanavir AUC decreased 31%, Cmax decreased 40%, Cmin decreased 80%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6467	Atazanavir Digoxin 852	Atazanavir			Digoxin			Potential for increased risk of digoxin toxicity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering digoxin dose may need to be decreased. Monitor digoxin level and adjust digoxin dose based on clinical signs and drug levels.
6372	Atazanavir Colchicine 757	Atazanavir			Colchicine			Potential for increased colchicine effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
6388	Atazanavir Bosentan 773	Atazanavir			Bosentan			Potential decreased antiviral effects of atazanavir	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Do not coadminister bosentan with unboosted atazanavir, For patients receiving atazanavir plus ritonavir for >10 days, start bosentan at 62.5mg daily or every other day based on individual tolerability, Discontinue bosentan at least 36 hours before starting atazanavir / ritonavir. At least 10 days after starting atazanavir / ritonavir, resume bosentan at 62.5mg daily or every other day based on individual tolerability.
6404	Atazanavir EFV 789	Atazanavir	400 mg daily on days 1-28	Atazanavir AUC increased 241%, Cmax increased 124%, Cmin increased 671%, half-life: increased 79%	Efavirenz	600 mg daily with ritonavir 200 mg on days 15-28	Not reported	Potential for increased atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6420	Atazanavir Posaconazole 805	Atazanavir	300 mg daily	Atazanavir AUC increased 268%, Cmax increased 155%	Posaconazole	400 mg BID		Potential for increased atazanavir adverse effects	Green: Administer standard doses	Administer standard doses	Monitor closely for atazanavir adverse effects during coadministration
6436	Atazanavir RTV 821	Atazanavir		Not studied; Potential increased atazanavir levels)	Ritonavir			Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
6452	Atazanavir RIF 837	Atazanavir	300 mg with 100 mg ritonavir daily x 10 d	Atazanavir AUC decreased 57%, Cmax decreased 56%, Cmin decreased 93%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6468	Atazanavir Proguanil 853	Atazanavir	300 mg with 100 mg ritonavir daily	Not reported	Proguanil	100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 41%, Cmax no significant change	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor for anti-malarial efficacy
6373	Atazanavir Daclatasvir 758	Atazanavir			Daclatasvir				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir	Decrease daclatasvir dose to 30 mg daily
6389	Atazanavir Cimetidine 774	Atazanavir			Cimetidine			Potential loss of antiviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Unboosted atazanavir 400 mg: give atazanavir 2 hrs before or 10 hours after H2-blocker. Single doses of H2-blockers should not exceed 20 mg of famotidine (or equivalent). Additionally, if treatment naive, total daily dose of H2 blocker should not exceed 40 mg of famotidine (or equivalent). Atazanavir 300 mg boosted with ritonavir or cobicistat: Give boosted atazanavir at same time as H2 blocker or 10 hours or more after. Total doses of H2 blocker should not exceed the equivalent of 40 mg BID famotidine (treatment naive) or 20 mg BID for (treatment experienced patients). If using tenofovir disoproxil fumarate, atazanavir, and H2 blocker in treatment experienced patient, increase atazanavir dose to 400 mg in addition to boosting with ritonavir or cobicistat.
6405	Atazanavir EFV 790	Atazanavir	400 mg daily on days 1-20	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%, half-life: decreased 27%	Efavirenz	600 mg daily on days 7-20	No significant change	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6421	Atazanavir Rosiglitazone 806	Atazanavir	300 mg daily with 100 mg ritonavir daily		Rosiglitazone	4 mg x 1	Rosiglitazone AUC decreased 17%	Potential decreased glycemic control	Green: Administer standard doses	Administer standard doses	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
6437	Atazanavir Ergotamine 822	Atazanavir			Ergotamine			Potential for increased ergotamine effects (eg, ergotism)	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Contraindicated. Use alternative agents.	5-HT agonists ("triptans")
6453	Atazanavir RIF 838	Atazanavir	300 mg with 100 mg ritonavir daily x 21 d	Atazanavir AUC decreased 72%, Cmax decreased 53%, Cmin decreased 98%	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6469	Atazanavir Disopyramide 854	Atazanavir			Disopyramide			Potential for increased risk of disopyramide adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for disopyramide toxicity
6374	Atazanavir Daclatasvir 759	Atazanavir	300 mg with ritonavir 100 mg daily	No significant change	Daclatasvir	20 mg daily	AUC(tau) increased 110%		Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir	Decrease daclatasvir dose to 30 mg daily when used with atazanavir / ritonavir. No dose adjustment necessary if used with unboosted atazanavir.
6390	Atazanavir TDF 775	Atazanavir	300 mg daily with ritonavir 100 mg daily on days 1-42	Atazanavir Cmax decreased 28%, AUC decreased 25%, Cmin decreased 26%, Ritonavir Cmax decreased 28%, AUC decreased 25%, Cmin no significant change	Tenofovir Disoproxil Fumarate	300 mg daily on days 15-42	Not reported	Potential loss of antiretroviral efficacy with lower atazanavir concentrationss. Potential for increased tenofovir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. Do not coadminister TDF with unboosted atazanavir (400 mg).
6406	Atazanavir EFV 791	Atazanavir	600 mg daily on days 7-20	Atazanavir (all values compared to atazanavir 400 mg daily) AUC decreased 21%, Cmax no significant change, Cmin decreased 59%	Efavirenz	600 mg daily on days 7-20	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
6422	Atazanavir Rosiglitazone 807	Atazanavir	400 mg daily		Rosiglitazone	4 mg x 1	Rosiglitazone AUC increased 35%	Potential for increased rosiglitazone adverse effects	Green: Administer standard doses	Administer standard doses	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
6438	Atazanavir EBR/GZR 823	Atazanavir	300 mg daily with ritonavir 100 mg daily	ATV AUC increased 43% by grazoprevir	Elbasvir / Grazoprevir	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	Contraindicated. Use alternative agents.
6454	Atazanavir RIF 839	Atazanavir	400 mg with 200 mg ritonavir daily x 10 d	Atazanavir AUC no significant change, Cmax decreased 18%, Cmin decreased 40%(compared to atazanavir 400 mg daily)	Rifampin	600 mg daily x 10 d	Not reported	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Contraindicated. Use alternative agents.	Rifabutin
6470	Atazanavir Mexiletine 855	Atazanavir			Mexiletine			Potential for increased risk of mexiletine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for mexiletine toxicity
6375	Atazanavir Diltiazem 760	Atazanavir	400 mg daily on days 1-11	No significant change	Diltiazem	180 mg daily on days 7-11 and 19-23	Diltiazem AUC increased 125%, Cmax increased 198%, Cmin decreased 59%	Potential for increased diltiazem effects (eg, hypotension, heart block)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of diltiazem	Reduce diltiazem dose by 50%. ECG monitoring is recommended.
6391	Atazanavir Pantoprazole 776	Atazanavir			Pantoprazole				Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Administer proton pump inhibitor at least 12 hours before atazanavir / cobicistat. Proton pump inhibitors should not exceed a dose equivalent to omeprazole 20 mg daily in protease inhibitor naive patients. Proton pump inhibitors are not recommended in protease inhibitor experienced patients.
6407	Atazanavir Famotidine 792	Atazanavir	300 mg daily with ritonavir 100 mg daily on d 1-20 (simultaneous administration)	Atazanavir AUC decreased 18%, Cmax no significant change, Cmin decreased 28%	Famotidine	40 mg BID on d 11-20	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6423	Atazanavir Dabigatran 808	Atazanavir			Dabigatran			Potential for increased risk of bleeding	Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6439	Atazanavir NVP 824	Atazanavir			Nevirapine	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	Contraindicated. Use alternative agents.
6455	Atazanavir EVG/c 840	Atazanavir	300 mg daily	Atazanavir Cmax decreased 24%, Cmin decreased 20%	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide	Elvitegravir 85 mg daily with cobicistat 150 mg daily	Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83%	Potential loss of antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Use alternative agents
6471	Atazanavir Flecainide 856	Atazanavir			Flecainide			Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for toxicity. Consider therapeutic drug monitoring
6376	Atazanavir Ethinyl estradiol / Norethindrone acetate 761	Atazanavir	400 mg daily x 14 days		Ethinyl estradiol / Norethindrone acetate	1 tab daily (7 / 7 / 7)	Norethindrone Cmax increased 67%, AUC increased 110%, Cmin increased 262%, Ethinyl estradiol AUC increased 48%, Cmax no significant change, Cmin increased 91%	Increased norethindrone and ethinyl estradiol effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of hormonal contraception	For unboosted atazanavir, use an oral contraceptive that contains no more than 30 mcg of ethinyl estradiol or recommend an alternative contraceptive method. Oral contraceptives containing less than 25mcg of ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied.	Non hormonal contraceptive method, barrier devices, condoms
6392	Atazanavir Esomeprazole 777	Atazanavir			Esomeprazole			Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir if boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 blockers
6408	Atazanavir Famotidine 793	Atazanavir	400 mg daily	Atazanavir AUC decreased 38%, Cmax decreased 42%, Cmin decreased 40%	Famotidine	40 mg Q12H	Not reported	Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6424	Atazanavir Dabigatran 809	Atazanavir			Dabigatran			Potential for increased risk of bleeding	Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6440	Atazanavir HMG-CoA Reductase Inhibitors 825	Atazanavir			Lovastatin			Increased lovastatin effects (eg, myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose), Pravastatin
6456	Atazanavir ETR 841	Atazanavir	400 mg daily	Atazanavir AUC decreased 17%, Cmin decreased 47%	Etravirine		Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58%	Potential increased etravirine effects, decreased atazanavir effects	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine	Use alternative agents
6472	Atazanavir Lidocaine 857	Atazanavir			Lidocaine				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor adverse effects and consider therapeutic drug monitoring.
6377	Atazanavir Itraconazole 762	Atazanavir			Itraconazole				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of itraconazole	Unless guided by therapeutic drug monitoring, limit doses of itraconazole to less than 200 mg daily when used with atazanavir / cobicistat.
6393	Atazanavir Omeprazole 778	Atazanavir	400 mg daily on d 1-12	Not reported	Omeprazole	40 mg x 1 on d 7 and 20	Omeprazole AUC increased 45%, Cmax increased 24%	Increased omeprazole effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6409	Atazanavir Famotidine 794	Atazanavir	300 mg daily with 100 mg ritonavir daily with tenofovir on d 11-17	Atazanavir AUC decreased 41%	Famotidine	20 mg BID on d 11-17		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6425	Atazanavir DTG 810	Atazanavir	300 mg daily with ritonavir 100 mg daily	Not reported	Dolutegravir	30 mg daily	Dolutegravir AUC increased 62%, Cmax increased 34%, Cmin increased 121%		Green: Administer standard doses	Administer standard doses
6441	Atazanavir Lurasidone 826	Atazanavir			Lurasidone			Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lurasidone	Contraindicated. Use alternative agents.
6457	Atazanavir Erythromycin 842	Atazanavir			Erythromycin				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination, use alternative antibiotics	Azithromycin
6473	Atazanavir Amiodarone 858	Atazanavir			Amiodarone			Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
6378	Atazanavir MVC 763	Atazanavir	400 mg daily	Not reported	Maraviroc	300 mg BID	Maraviroc AUC increased 257%, Cmax increased 109%, Cmin increased 319%	Potential increase in maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Decrease maraviroc dose to 150 mg BID
6394	Atazanavir Omeprazole 779	Atazanavir	300 mg daily with 100 mg ritonavir daily on d 7-16 then 400 mg atazanavir daily with 100 mg ritonavir daily on d 17-23	Atazanavir AUC decreased 30%, Cmin decreased 31%, Cmax decreased 31%	Omeprazole	20 mg daily on d 17-23		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6410	Atazanavir Famotidine 795	Atazanavir	400 mg daily on d 1-12 (simultaneous administration)	Atazanavir AUC decreased 41%, Cmax decreased 47%, Cmin decreased 42%	Famotidine	40 mg BID on d 7-12		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6426	Atazanavir DTG 811	Atazanavir	400 mg daily	Not reported	Dolutegravir	30 mg daily	Dolutegravir AUC increased 91%, Cmax increased 50%, Cmin increased 180%		Green: Administer standard doses	Administer standard doses
6442	Atazanavir Pimozide 827	Atazanavir			Pimozide			Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Contraindicated. Use alternative agents.
6458	Atazanavir Apixaban 843	Atazanavir			Apixaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination, use alternative anticoagulant	Dabigatran
6474	Atazanavir Propafenone 859	Atazanavir			Propafenone			Potential for increased propafenone effects (eg, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for toxicity.
6379	Atazanavir MVC 764	Atazanavir	300 mg daily with 100 mg ritonavir daily	Not reported	Maraviroc	300 mg BID	Maraviroc AUC increased 388%, Cmax increased 167%, Cmin increased 567%	Potential increase in maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Decrease maraviroc dose to 150 mg BID
6395	Atazanavir Omeprazole 780	Atazanavir	300 mg QPM with 100 mg ritonavir QPM on d 7-16, 17-23	Atazanavir AUC decreased 42%, Cmax decreased 39%, Cmin decreased 46%	Omeprazole	20 mg daily on d 17-23		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6411	Atazanavir Famotidine 796	Atazanavir	400 mg on d 1-6, d 7-12 (10 hr after, 2 hrs before famotidine)	Atazanavir Cmin decreased 31%	Famotidine	40 mg daily on d 7-12		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6427	Atazanavir SOF/VEL 812	Atazanavir	300 mg with ritonavir 100 mg daily	Atazanavir Cmax increased 9%, AUC increased 20%, Cmin increased 39%.	Sofosbuvir / Velpatasvir	400 mg / 100 mg	Sofosbuvir AUC increased 22%. Velpatasvir Cmax increased 55%, AUC increased 142%, Cmin increased 301%		Green: Administer standard doses	Administer standard doses
6443	Atazanavir Quetiapine 828	Atazanavir			Quetiapine			Increased quentiapine effects.	Red: Avoid combination	Do not coadminister: Potential for increased levels of quentiapine. If coadministration is necessary: reduce dose to 1 / 6 of current dose.	Contraindicated. Use alternative agents.
6459	Atazanavir Phenytoin 844	Atazanavir			Phenytoin			Potential loss of antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents	Gabapentin Lamotrigine Tiagabine Topiramate
6475	Atazanavir Quinidine 860	Atazanavir			Quinidine			Potential for increased quinidine effects (e.g. cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution. Monitor for toxicity.
6380	Atazanavir Pitavastatin 765	Atazanavir	300 mg daily x 5 days	No significant change	Pitavastatin	4 mg daily	Pitavastatin AUC increased 31%, Cmax increased 60%	Potential for increased pitavastatin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pitavastatin	Start at lowest dose and titrate to effect
6396	Atazanavir Omeprazole 781	Atazanavir	400 mg daily with ritonavir 100 mg daily x 20 d	Atazanavir AUC decreased 61%, Cmax decreased 56%, Cmin decreased 66%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6412	Atazanavir Famotidine 797	Atazanavir	400 mg atazanavir with 100 mg ritonavir on d 11-20	Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 14%(compared to 300 mg atazanavir with 100 mg ritonavir daily)	Famotidine	40 mg Q12H on d 11-20		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6428	Atazanavir Atenolol 813	Atazanavir	400 mg daily on days 1-11	Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 26%	Atenolol	50 mg daily on days 7-11 and 19-23	Atenolol AUC increased 25%, Cmax increased 34%, Cmin no significant change		Green: Administer standard doses	Administer standard doses
6444	Atazanavir Ranolazine 829	Atazanavir			Ranolazine			Potential increase in ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias).	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Contraindicated. Use alternative agents.
6460	Atazanavir Phenobarbital 845	Atazanavir			Phenobarbital			Potential loss of antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination or use alternative agents	Gabapentin Lamotrigine Tiagabine Topiramate
6476	Atazanavir Midazolam 861	Atazanavir			Midazolam			Potential for increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.	Lorazepam, Oxazepam, Temazepam, Trazodone
6381	Atazanavir RFB 766	Atazanavir	600 mg daily on days 11-20	Not reported	Rifabutin	300 mg daily on days 1-10, then 150 mg daily on days 11-20	Rifabutin AUC increased 110%, Cmax increased 118%, Cmin increased 243%, 25-O-desacetylrifabutin AUC increased 2101%, Cmax increased 720%, Cmin increased 7460%	Increased rifabutin effects (eg, uveitis)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6397	Atazanavir Omeprazole 782	Atazanavir	300 mg with ritonavir 100 mg daily with 8 oz cola x 20 d	Atazanavir AUC decreased 70%, Cmax decreased 66%, Cmin decreased 76%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6413	Atazanavir Famotidine 798	Atazanavir	300 mg daily with 100 mg ritonavir	No significant change	Famotidine	20 mg BID on d 11-17 (simultaneous administration with morning atazanavir / ritonavir)			Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
6429	Atazanavir Fluconazole 814	Atazanavir	300 mg daily with ritonavir 100 mg daily x 10 days	No significant change	Fluconazole	200 mg daily x 10 days	No significant change		Green: Administer standard doses	Administer standard doses
6445	Atazanavir Salmeterol 830	Atazanavir			Salmeterol			QT prolongation, palpitations, and sinus tachycardia.	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	Contraindicated. Use alternative agents.
6461	Atazanavir Clarithromycin 846	Atazanavir			Clarithromycin				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider alternative antibiotics	Azithromycin
6477	Atazanavir Fluticasone 862	Atazanavir			Fluticasone			Decreased plasma cortisol concentrations (eg, Cushing's syndrome, adrenal suppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use with caution with atazanavir, use with atazanavir / ritonavir is not recommended unless the potential benefit outweighs the risk	Beclomethasone
6382	Atazanavir RFB 767	Atazanavir	400 mg daily on days 1-14, 400 mg daily with ritonavir 100 mg daily on days 15-28	Atazanavir AUC increased 191%, Cmax increased 81%	Rifabutin	150 mg daily on days 15-28	Not reported	Potential increase in atazanavir adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
6398	Atazanavir Omeprazole 783	Atazanavir	300 mg daily with ritonavir 100 mg daily x 20 d	Atazanavir AUC decreased 76%, Cmax decreased 72%, Cmin decreased 78%	Omeprazole	40 mg daily x 10 d		Potential loss of antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.	H2 receptor antagonists
6414	Atazanavir EE/NGM 799	Atazanavir	300 mg atazanavir daily with 100 mg ritonavir daily		Ethinyl estradiol / Norgestimate		Ethinyl estradiol AUC decreased 19%, Cmax decreased 16%, Cmin decreased 37% 17-deacetyl norgestimate AUC increased 85%, Cmax increased 68%, Cmin increased 102%		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of hormonal contraception	With ritonavir boosted atazanavir, use an oral contraceptive containing at least 35 mcg of ethinyl estradiol. Oral contraceptives containing progestins other than norethindrone or norgestimate have not been studied.	Non-hormonal contraceptives, barrier devices, condoms
6430	Atazanavir Ketoconazole 815	Atazanavir	400 mg daily on days 1-13	No significant change	Ketoconazole	200 mg daily on days 7-13	Not reported		Green: Administer standard doses	Administer standard doses
6446	Atazanavir Simvastatin 831	Atazanavir			Simvastatin			Potential Increased simvastatin effects (eg, myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Contraindicated. Use alternative agents.	Atorvastatin (low dose), Pravastatin
6462	Atazanavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 847	Atazanavir			Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir				Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Do not coadminister
6478	Atazanavir Voriconazole 863	Atazanavir			Voriconazole	200 mg PO Q12H	Voriconazole AUC decreased 39% when given with ritonavir 100 mg BID	Potential decreased voriconazole antifungal effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	With unboosted atazanavir no dose adjustment necessary, monitor for toxicity. Do not coadminister with boosted protease inhibitors unless benefit outweighs risks. Consider therapeutic drug monitoring.
6495	Darunavir Clarithromycin 880	Darunavir	400 mg with 100 mg ritonavir BID	Cmax decrease 17%, AUC decrease 13%, Cmin increase 1%	Clarithromycin	500 mg BID	Cmax increase 26%, AUC increased 57%, Cmin increase 174%	Increased risk of antibacterial adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	In patients with CrCl 30-60 mL / min, reduce dose of clarithromycin by 50%. In patients with CrCl <30 mL / min, reduce clarithromycin dose by 75%. Monitor for clarithromycin-related toxicities and / or consider alternative macrolide.	Azithromycin
6511	Darunavir Methadone 896	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Methadone	55-200 mg once daily (stable dose)	R-methadone: Cmax decrease 24%, AUC decrease 16%, Cmin decrease 15%; S-methadone: Cmax decrease 44%, AUC decrease 36%, Cmin decrease 40%	May decrease methadone effects (e.g. withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6527	Darunavir SOF 912	Darunavir	800 mg with 100 mg ritonavir once daily	No significant change	Sofosbuvir	400 mg x 1	Cmax increase 45%, AUC increase 34%		Green: Administer standard doses	Administer standard doses
6543	Darunavir Eplerenone 928	Darunavir			Eplerenone			Potential for increased risk of eplerenone adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased eplerenone levels	Contraindicated. Use alternative agents.
6559	Darunavir Terfenadine 944	Darunavir			Terfenadine			Potential for increased risk of terfenadine adverse effects (e.g. cardiac arrhythmias)	Red: Avoid combination	Do not coadminister: Potential for increased levels of terfendaine	Use alternative agents	Cetirizine, Fexofenadine, Loratadine
6575	Darunavir Voriconazole 960	Darunavir			Voriconazole			Potential decreased voriconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid coadministering with boosted protease inhibitors unless benefit outweighs risks. If coadministering, consider therapeutic drug monitoring.
6591	Darunavir Oxycodone 976	Darunavir			Oxycodone			Potential for increased risk of oxycodone adverse effects (e.g. respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Clinical monitoring is recommended
6607	Darunavir Salmeterol 992	Darunavir			Salmeterol			Potential for increased risk of salmeterol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
6623	Darunavir Diazepam 1008	Darunavir			Diazepam			Potential for increased risk of diazepam adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate diazepam at low dose and titrate to effect	Lorazepam, Oxazepam, Temazepam
6639	Darunavir Verapamil 1024	Darunavir			Verapamil			Potential for increased risk of verapamil adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor verapamil adverse effects
6496	Darunavir Colchicine 881	Darunavir			Colchicine			Increased risk of colchicine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
6512	Darunavir Paroxetine 897	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Paroxetine	20 mg once daily	Cmax decrease 36%, AUC decrease 39%, Cmin decrease 37%	Potential decreased paroxetine effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of paroxetine	Titrate paroxetine to effect; monitor for continued antidepressant response if darunavir / ritonavir initiated
6528	Darunavir LDV/SOF 913	Darunavir	800 mg with 100 mg ritonavir once daily	No significant change	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Ledipasvir Cmax increase 45%, AUC increase 39%, Cmin increase 39%; Sofosbuvir Cmax increase 45%, AUC increase 34%		Green: Administer standard doses	Administer standard doses
6544	Darunavir Everolimus 929	Darunavir		Not studied	Everolimus		Not studied (may increase everolimus levels)	Potential for increased risk of everolimus adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased everolimus levels	Use alternative agents
6560	Darunavir Triazolam 945	Darunavir			Triazolam			Potential for increased risk of triazolam adverse effects (e.g. increased sedation, confusion, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Contraindicated. Use alternative agents.	Lorazepam, Oxazepam, Temazepam
6576	Darunavir Phenobarbital 961	Darunavir			Phenobarbital			Potential loss of antiviral efficacy, Potential for decreased phenobarbital effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor and adjust phenytoin levels as indicated and monitor viral load.	Gabapentin, Lamotrigine, Tiagabine, Topiramate
6592	Darunavir Tramadol 977	Darunavir			Tramadol			Potential for increased risk of tramadol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Clinical monitoring is recommended. Dose reduction may be needed
6608	Darunavir EVG/c 993	Darunavir	800 mg darunavir once daily	Cmin decreased 21%	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide	150 / 150 mg once daily	Elvitegravir AUC decrease 20%, Cmin decrease 52%; Cobicistat AUC decrease 15-20%	Potential for decreased or increased elvitegravir, cobicistat, and / or darunavir effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents. One study supports clinical use of elvitegravir / cobicistat with darunavir 800 mg daily in treatment experienced patients.
6624	Darunavir Estazolam 1009	Darunavir			Estazolam			Potential for increased risk of estazolam adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate estazolam at low dose and titrate to effect
6640	Darunavir Diltiazem 1025	Darunavir			Diltiazem			Potential for increased risk of diltiazem adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, titrate to effect and monitor diltiazem adverse effects
6481	Darunavir Buprenorphine / naloxone 866	Darunavir	600 mg with 100 mg ritonavir BID	Not studied	Buprenorphine / naloxone	8-16 / 2-4 mg	Norbuprenorphine: Cmax increase 36%, AUC increase 46%, Cmin increase 71%	Potential for increased buprenorphine / naloxone effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of buprenorphine / naloxone	If initiating buprenorphine / naloxone in patients taking DRV / r or DRV / c, carefully titrate dose to desired effect
6497	Darunavir Digoxin 882	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Digoxin	0.4 mg x 1	Cmax increase 15%, AUC increase 36%	Increased risk of digoxin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of digoxin	Initiate lowest dose digoxin and titrate to desired clinical effect
6513	Darunavir Sertraline 898	Darunavir	400 mg with 100 mg ritonavir BID	No significant change	Sertraline	50 mg once daily	Cmax decrease 44%, AUC decrease 49%, Cmin decrease 49%	Potential decreased sertraline effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of sertraline	Titrate sertraline to effect; monitor to ensure continued response if darunavir / ritonavir initiated
6529	Darunavir Ranitidine 914	Darunavir	400 mg with 100 mg ritonavir BID	No significant change	Ranitidine	150 mg BID	Not reported		Green: Administer standard doses	Administer standard doses
6545	Darunavir Flibanserin 930	Darunavir			Flibanserin			Potential for increased risk of flibanserin adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased flibanserin levels	Contraindicated. Use alternative agents.
6561	Darunavir Lurasidone 946	Darunavir			Lurasidone			Potential for increased risk of lurasidone adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased lurasidone levels	Contraindicated. Use alternative agents.
6577	Darunavir Phenytoin 962	Darunavir			Phenytoin			Potential loss of antiviral efficacy, Potential for decreased phenytoin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor and adjust phenytoin levels as indicated and monitor viral load.	Gabapentin, Lamotrigine, Tiagabine, Topiramate
6593	Darunavir Eslicarbazepine 978	Darunavir			Eslicarbazepine			Potential loss of antiviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended
6609	Darunavir Clonazepam 994	Darunavir			Clonazepam			Potential for increased risk of clonazepam adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Clinical monitoring is recommended
6625	Darunavir Imipramine 1010	Darunavir			Imipramine			Potential for increased risk of imipramine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate imipramine at low dose. Monitor for CNS and cardiovascular effects.
6641	Darunavir Carvedilol 1026	Darunavir			Carvedilol			Potential for increased risk of carvedilol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, use caution and clinical monitoring is recommended
6482	Darunavir Canagliflozin 867	Darunavir			Canagliflozin			Potential for decreased glucose lowering effect	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of canagliflozin	If a patient is already tolerating canagliflozin 100 mg daily, increase canagliflozin dose to 200 mg daily. If a patient is already tolerating canagliflozin 200 mg daily and requires additional glycemic control, management strategy is based on renal function, 300 mg if eGFR>60 or add another agent if eGFR<60
6498	Darunavir MVC 883	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Maraviroc	150 mg BID	Cmax increase 129%, AUC increase 305%, Cmin increase 700%	Potential for increased maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
6514	Darunavir Warfarin 899	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Warfarin	10 mg x 1	S-warfarin Cmax decrease 8%, AUC decrease 21%	Decreased warfarin effects (e.g. decreased INR, increased risk of clotting)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of warfarin	If coadministering, monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
6530	Darunavir Omeprazole 915	Darunavir	400 mg with 100 mg ritonavir BID	No significant change	Omeprazole	20 mg once daily	Not reported		Green: Administer standard doses	Administer standard doses
6546	Darunavir G/P 931	Darunavir			Glecaprevir / Pibrentasvir			Potential for increased glecaprevir / pibrentasvir adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased glecaprevir / pibrentasvir levels	Use alternative agents
6562	Darunavir Mexiletine 947	Darunavir			Mexiletine			Potential for increased risk of mexiletine adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased mexiletine levels	Use alternative agents
6578	Darunavir Dabigatran 963	Darunavir			Dabigatran			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative anticoagulant
6594	Darunavir Oxcarbazepine 979	Darunavir			Oxcarbazepine			Potential loss of antiviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended
6610	Darunavir Drospirenone / Ethinyl estradiol 995	Darunavir			Drospirenone / Ethinyl estradiol			Potential for increased risk of drospirenone adverse effects (hyperkalemia) or decreased contraceptive efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Clinical monitoring is recommended
6626	Darunavir CsA 1011	Darunavir		Not studied	Cyclosporine		Not studied (may increase cyclosporine levels)	Potential for increased risk of cyclosporine adverse effects (supratherapeutic immunosuppression, renal toxicity)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lower dose of immunosuppressant, monitor concentrations and toxicity, consult with specialist, and adjust dose as necessary
6642	Darunavir Metoprolol 1027	Darunavir			Metoprolol			Potential for increased risk of metoprolol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, use caution and clinical monitoring is recommended
6483	Darunavir Lamotrigine 868	Darunavir			Lamotrigine			Potential for decreased anticonvulsant effects	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of lamotrigine	Monitor anticonvulsant level and adjust accordingly
6499	Darunavir MVC 884	Darunavir	600 mg with 100 mg ritonavir BID with etravirine 200 mg BID	Not reported	Maraviroc	150 mg BID	Cmax increase 77%, AUC increase 210%, Cmin increase 427%	Potential for increased maraviroc adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
6515	Darunavir Dabigatran 900	Darunavir			Dabigatran				Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6531	Darunavir SOF/VEL 916	Darunavir	800 mg with 100 mg ritonavir once daily	Cmax decrease 10%, AUC decrease 8%, Cmin decrease 13%.	Sofosbuvir / Velpatasvir	400 / 100 mg	Sofosbuvir Cmax decrease 38%, AUC decrease 28%; Velpatasvir Cmax decrease 24%, AUC decrease 16%.		Green: Administer standard doses	Administer standard doses
6547	Darunavir Irinotecan 932	Darunavir			Irinotecan			Potential for increased risk of irinotecan adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased irinotecan levels	Discontinue DRV / c at least 1wk prior to starting irinotecan. Do not coadminister unless there are no therapeutic alternatives
6563	Darunavir Naloxegol 948	Darunavir			Naloxegol			Potential for increased risk of precipitating opioid withdrawal	Red: Avoid combination	Do not coadminister: Potential for increased naloxegol levels	Contraindicated. Use alternative agents.
6579	Darunavir Ticagrelor 964	Darunavir			Ticagrelor			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative antiplatelet agent
6595	Darunavir Vinblastine 980	Darunavir			Vinblastine			Potential for increased risk of vinblastine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider temporarily withholding cobicistat-containing ARV regimen in patients who develop significant hematologic or gastrointestinal adverse effects. If ARV regimen must be withheld for a prolonged period of time, initate a revised regimen
6611	Darunavir Isavuconazole 996	Darunavir			Isavuconazole			Potential for increased risk of darunavir and isavuconazole adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established, monitor for increased DRV and / or antifungal adverse reactions
6627	Darunavir Nortiptyline 1012	Darunavir			Nortiptyline			Potential for increased risk of nortriptyline adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate nortriptyline at low dose. Monitor for CNS and cardiovascular effects.
6643	Darunavir Timolol 1028	Darunavir			Timolol			Potential for increased risk of timolol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, use caution and clinical monitoring is recommended
6484	Darunavir Omeprazole 869	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Omeprazole	40 mg x 1	Cmax decrease 34%, AUC decrease 42%	Potential decreased omeprazole efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of omeprazole	Consider using alternative agents. If coadministering, monitor for omeprazole efficacy. If no symptomatic relief, increase dose to no more than 40 mg once daily
6500	Darunavir Pravastatin 885	Darunavir	600 mg with 100 mg ritonavir BID	Not studied	Pravastatin	40 mg x 1	Cmax increase 63%, AUC increase 81%	Increased risk of pravastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pravastatin	Use lowest possible starting dose, monitor for toxicity and titrate.
6516	Darunavir Edoxaban 901	Darunavir			Edoxaban				Green: Administer standard doses	Administer standard doses	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
6532	Darunavir ETR 917	Darunavir	600 mg with 100 mg ritonavir BID		Etravirine	200 mg twice daily			Green: Administer standard doses	Administer standard doses
6548	Darunavir Ivabradine 933	Darunavir			Ivabradine			Potential for increased risk of ivabradine adverse effects (e.g. prolonged QT, cardiac arrythmias)	Red: Avoid combination	Do not coadminister: Potential for increased ivabradine levels	Use alternative agents
6564	Darunavir Perphenazine 949	Darunavir			Perphenazine			Potential for increased risk of perphenazine adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased perphenazine levels	Contraindicated. Use alternative agents.
6580	Darunavir Vorapaxar 965	Darunavir			Vorapaxar			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative antiplatelet agent
6596	Darunavir Vincristine 981	Darunavir			Vincristine			Potential for increased risk of vincristine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider temporarily withholding cobicistat-containing ARV regimen in patients who develop significant hematologic or gastrointestinal adverse effects. If ARV regimen must be withheld for a prolonged period of time, initate a revised regimen
6612	Darunavir Posaconazole 997	Darunavir			Posaconazole			Potential for increased risk of darunavir and posaconazole adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established, monitor for increased DRV and / or antifungal adverse reactions
6628	Darunavir Trazodone 1013	Darunavir			Trazodone			Potential for increased risk of trazodone adverse effects (e.g. nausea, dizziness, hypotension, syncope)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate trazodone at low dose. Monitor for CNS and cardiovascular effects.
6644	Darunavir CBZ 1029	Darunavir	600 mg with 100 mg ritonaivr BID	Darunavir: No significant change; Ritonavir cmax decreased 44%, AUC decreased 49%, Cmin decreased 56%	Carbamazepine	200 mg BID	Cmax increase 43%, AUC increase 45%, Cmin increase 54%	Increased carbamazepine effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor anticonvulsant level and adjust accordingly. Consider carbamazepine dose reduction by 25-50%. Monitor antiviral efficacy
6485	Darunavir Valproic Acid 870	Darunavir			Valproic Acid			Potential for decreased anticonvulsant effects	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of valproic acid	Monitor anticonvulsant level and adjust accordingly
6501	Darunavir RFB 886	Darunavir	600 mg with 100 mg ritonavir BID	Darunavir Cmax increase 42%, AUC increase 57%, Cmin increase 75%; Ritonavir Cmax increase 68%, AUC increase 66%, Cmin increase 31%	Rifabutin	150 mg every other day	Rifabutin: Cmax decrease 28%, AUC decrease 7%, Cmin increase 64%; 25-O-desacetylrifabutin: Cmax increase 377%, AUC increase 881%, Cmin increase 2610%	Increased darunavir and rifabutin effects. Note that lower rifabutin exposure has been reported in HIV- infected patients as compared to healthy study participants.	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Dose reduction of RFB by 75% of usual dose is recommended, such as rifabutin 150 mg every other day. Monitor for antimycobacterial activity and adverse events. Consider therapeutic drug monitoring.
6517	Darunavir Daclatasvir 902	Darunavir	600 mg with 100 mg ritonavir BID	No significant change	Daclatasvir	30 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses	No dose adjustment necessary
6533	Darunavir Z-Pak 918	Darunavir			Azithromycin				Green: Administer standard doses	Administer standard doses
6549	Darunavir Alfuzosin 934	Darunavir			Alfuzosin			Potential for increased risk of alfuzosin adverse effects (e.g. hypotension)	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin	Contraindicated. Use alternative agents.
6565	Darunavir Suvorexant 950	Darunavir			Suvorexant			Potential for increased risk of suvorexant adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased suvorexant levels	Use alternative agents
6581	Darunavir Apixaban 966	Darunavir			Apixaban			Potential for increased bleeding risk	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination; use alternative anticoagulant	Dabigatran, betrixaban, edoxaban
6597	Darunavir Quetiapine 982	Darunavir			Quetiapine			Potential for increased risk of quetiapine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. If coadministering, reduce quetiapine dose to 1 / 6 of current dose and monitor for quetiapine adverse reactions
6613	Darunavir Itraconazole 998	Darunavir			Itraconazole			Potential for increased darunavir and itraconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established; if co-administration needed, itraconazole dose should not exceed 200 mg daily
6629	Darunavir Zolpidem 1014	Darunavir			Zolpidem			Potential for increased risk of zolpidem adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate zolpidem at low dose and titrate to effect
6645	Darunavir Dextromethrophan 1030	Darunavir	600 mg with 100 mg ritonavir BID	Not reported	Dextromethrophan	30 mg x 1	Cmax increase 127%, AUC increase 170%	Potential for increased dextromethorphan effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor for dextromethorphan adverse effects
6486	Darunavir Atorvastatin 871	Darunavir	300 mg with 100 mg ritonavir BID	Not reported	Atorvastatin	40 mg once daily on days 1-4, then 10 mg once daily on days 4-7	Cmax decrease 44%, AUC decrease 15%, Cmin increase 81% (10 mg daily with darunavir / ritonavir compared to atorvastatin 40 mg daily alone)	Increased risk of atorvastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atorvastatin	Consider using alternative agents. If coadministering, consider low dose atorvastatin and doses < 20 mg. Monitor for myopathy
6502	Darunavir Risperidone 887	Darunavir			Risperidone			Potential for increased risk of risperidone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of risperidone	If coadministering, dose reduction may be necessary